Hemophilia Treatment Market By Product (Recombinant coagulation factor concentrates, Plasma derived coagulation factor concentrates, Antifibrinolytic agents, and Desmopressin), By Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C) By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospitals, and Others), and By Region - Trends, Analysis and Forecast till 2030

Major players introducing new medications

Key industry players have recently introduced innovative medications to treat hemophilia; the approval of these medications is anticipated to generate significant growth potential for the market over the projected period. For example, in May 2017, the FDA in the United States approved Novo Nordisk's Biologics License Application for REBINYN (Coagulation Factor IX (Recombinant), GlycoPEGylated), which is intended for the treatment of hemophilia B in adults and children. The FDA approved Bayer AG's factor VIII hemophilia medication, Jivi, in March 2017. This medication is intended to treat hemophilia A in prevention.

Getting new medications approved

Significant competitors in the market are also concentrating on getting their innovative hemophilia treatment medications approved in crucial areas like Asia-Pacific and Europe. Over the projection period, the approval of such medicines in key regions is anticipated to fuel market expansion. For example, the hemophilia treatment medication Jivi from Bayer AG was approved in Europe in August 2018 and Japan in September 2018.